First results of a first-in-man proof of concept study of an anti-CD4mAb-fragment for the imaging of chronic inflammation in patients with active rheumatoid arthritis

被引：0
|
作者：
Siegert, J. [1 ]
Brecht, B. [1 ]
Hesse, S. [2 ]
Schindler, C. [1 ]
Pigla, U. [3 ]
Sabri, O. [2 ]
Kirch, W. [1 ]
机构：
[1] Tech Univ Dresden, Fac Med, Inst Clin Pharmacol, Dresden, Germany
[2] Univ Leipzig, Klin & Poliklin Nucl Med, Leipzig, Germany
[3] Biotectid GmbH, Leipzig, Germany
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2007年 / 101卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
C-11
引用
收藏
页码：369 / 369
页数：1
相关论文
共 36 条
  • [21] Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)
    Huizinga, T. W. J.
    Batalov, Anastas
    Stoilov, Rumen
    Lloyd, Eric
    Wagner, Thomas
    Saurigny, Didier
    Souberbielle, Bernard
    Esfandiari, Ehsanollah
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [22] BMS-790052 IS A FIRST-IN-CLASS POTENT HEPATITIS C VIRUS (HCV) N55A INHIBITOR FOR PATIENTS WITH CHRONIC HCV INFECTION: RESULTS FROM A PROOF-OF-CONCEPT STUDY
    Nettles, R.
    Chien, C.
    Chung, E.
    Persson, A.
    Gao, Min
    Belema, M.
    Meanwell, Nicholas A.
    DeMicco, Michael P.
    Marbury, Thomas C.
    Goldwater, R.
    Northup, P.
    Coumbis, J.
    Kraft, Walter K.
    Charlton, Michael R.
    Lopez-Talavero, Juan C.
    Grasela, Denise
    HEPATOLOGY, 2008, 48 (04) : 1025A - 1025A
  • [23] Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
    Smolen, Josef S.
    Weinblatt, Michael E.
    Sheng, Shihong
    Zhuang, Yanli
    Hsu, Benjamin
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (09) : 1616 - 1625
  • [24] A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
    Sikic, Branimir I.
    Lakhani, Nehal J.
    Patnaik, Amita
    Shah, Sumit
    Chandana, Sreenivasa R.
    Rasco, Drew W.
    Colevas, A. Dimitrios
    O'Rourke, Timothy J.
    Papadopoulos, Kyriakos P.
    Fisher, George A.
    Chao, Mark
    Agoram, Balaji
    Chen, James Y.
    Huang, Jenny
    Axt, Matthew
    Majeti, Ravindra
    Weissman, Irving L.
    Takimoto, Chris H. M.
    Pegram, Mark D.
    Padda, Sukhmani Kaur
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Impact of Ustekinumab on Active Inflammation and Post-Inflammatory Structural Changes As Detected By Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis: Results of a 28-Week, Prospective, Open-Label, Proof-of-Concept Study.
    Poddubnyy, Denis
    Hermann, Kay-Geert
    Callhoff, Johanna
    Listing, Joachim
    Sieper, Joachim
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1145 - S1145
  • [26] Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
    Burmester, Gerd R.
    Feist, E.
    Kellner, H.
    Braun, J.
    Iking-Konert, C.
    Rubbert-Roth, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (05) : 755 - 759
  • [27] Improved quality of life (QoL) with rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): Results from a phase III randomized controlled study (SERENE)
    Deodhar, Atul
    Isaacs, John
    Rigby, William
    Racewicz, Artur J.
    Abud-Mendoza, Carlos
    McLean, Lachy
    Armstrong, Gillian K.
    Reynard, Mark
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S302 - S302
  • [28] Results of a phase II, double-blind, randomized study of a nondepleting anti-CD4 monoclonal antibody (Clenoliximab) given in combination with methotrexate (MTX) in patients with moderate to severe rheumatoid arthritis (RA)
    Luggen, ME
    Schechtman, J
    Kivitz, A
    Greenwald, M
    Forstot, J
    Boling, E
    Aldworth, J
    Ingram, M
    Totoritis, M
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 99 - 99
  • [29] RESULTS FROM A 2-PART, PROOF-OF-CONCEPT, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
    Hsu, B.
    Sheng, S.
    Smolen, J. S.
    Weinblatt, M. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 188 - 188
  • [30] Results From a 2-Part, Proof-of-Concept, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Sirukumab, a Human Anti-Interleukin-6 Monoclonal Antibody, in Active Rheumatoid Arthritis Patients Despite Methotrexate Therapy.
    Hsu, Benjamin
    Sheng, Shihong
    Smolen, Josef
    Weinblatt, Michael
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1034 - S1034
1234